AL 101

Drug Profile

AL 101

Alternative Names: BMS-906024

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours; T cell lymphoma

Most Recent Events

  • 13 Jun 2018 BMS 906024 is still in phase I trials for Precursor T-cell lymphoblastic leukaemia lymphoma (Combination therapy, Second-line therapy or greater), T-cell lymphoma (Combination therapy, Second-line therapy or greater) in France, Germany and USA
  • 01 Jun 2018 Efficacy, adverse events, pharmacodynamics and pharmacokinetic data from a phase I study in Advanced solid tumours study (Late-stage) presented at 54th Annual Meeting of Clinical Oncology (ASCO – 2018)
  • 07 Feb 2018 Bristol-Myers Squibb completes a phase I trial for Precursor T-cell lymphoblastic leukaemia lymphoma & T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, France and Germany (IV) (NCT01363817)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top